Small molecule · Inhibitor of KRAS G12V mutant protein (GTP-bound ON form) (KRAS) · developed by Revolution Medicines
RMC-5127 is an orally bioavailable, non-covalent inhibitor of the active GTP-bound form of the KRAS G12V mutant protein. It binds cyclophilin A to form a tri-complex that sterically blocks downstream effector binding, and it is studied in non-small cell lung cancer, colorectal cancer, and pancreatic cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07349537 | Phase 1 | Non-small Cell Lung Cancer (NSCLC) | Recruiting | RVMD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsColorectal Cancer (CRC)CRCLung Cancer (NSCLC)Non-small Cell Lung Cancer (NSCLC)NSCLCPancreatic AdenocarcinomaPancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)PDAC
See RVMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RVMD catalysts and pipeline →